Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Franchi

Showing results (91-100 of 147) with videos related to

Pageof 15
Sort By:
Thrombosis and Haemostasis|August 5, 2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y<sub>12</sub> receptor inhibitorsFabiana Rollini, Francesco Franchi, Kamaldeep Singh, et al.
JACC. Cardiovascular Interventions|November 5, 2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With CangrelorFrancesco Franchi, Fabiana Rollini, Mattia Galli, et al.
Thrombosis and Haemostasis|December 4, 2015
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled studyFrancesco Franchi, Fabiana Rollini, Jung Rae Cho, et al.
Journal of the American College of Cardiology|September 6, 2014
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery diseaseDominick J Angiolillo, Joseph A Jakubowski, José Luis Ferreiro, et al.
JACC. Cardiovascular Interventions|June 29, 2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind InvestigationJung Rae Cho, Fabiana Rollini, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|September 26, 2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic InvestigationFrancesco Franchi, Fabiana Rollini, Jung Rae Cho, et al.
JACC. Cardiovascular Interventions|March 18, 2014
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patientsFabiana Rollini, Francesco Franchi, Antonio Tello-Montoliu, et al.
Journal of the American Heart Association|March 13, 2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y<sub>12</sub> Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO TrialFrancesco Franchi, Stefan K James, Tatevik Ghukasyan Lakic, et al.
Clinical Pharmacology and Therapeutics|July 20, 2024
Evaluating the Effect of Estimating Renal Function With the CKD-EPI 2021 Equation on the ABCD-GENE Score for Clopidogrel Response PredictionMaryam Jamal AlSaeed, Cameron D Thomas, Francesco Franchi, et al.
Journal of the American College of Cardiology|March 26, 2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH StudyFabiana Rollini, Francesco Franchi, Jenny Hu, et al.
Pageof 15

Showing results (91-100 of 147) with videos related to

Sort By:
Pageof 15
Thrombosis and Haemostasis|August 5, 2016
Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y<sub>12</sub> receptor inhibitorsFabiana Rollini, Francesco Franchi, Kamaldeep Singh, et al.
JACC. Cardiovascular Interventions|November 5, 2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With CangrelorFrancesco Franchi, Fabiana Rollini, Mattia Galli, et al.
Thrombosis and Haemostasis|December 4, 2015
Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled studyFrancesco Franchi, Fabiana Rollini, Jung Rae Cho, et al.
Journal of the American College of Cardiology|September 6, 2014
Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery diseaseDominick J Angiolillo, Joseph A Jakubowski, José Luis Ferreiro, et al.
JACC. Cardiovascular Interventions|June 29, 2015
Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind InvestigationJung Rae Cho, Fabiana Rollini, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|September 26, 2015
Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic InvestigationFrancesco Franchi, Fabiana Rollini, Jung Rae Cho, et al.
JACC. Cardiovascular Interventions|March 18, 2014
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patientsFabiana Rollini, Francesco Franchi, Antonio Tello-Montoliu, et al.
Journal of the American Heart Association|March 13, 2019
Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y<sub>12</sub> Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO TrialFrancesco Franchi, Stefan K James, Tatevik Ghukasyan Lakic, et al.
Clinical Pharmacology and Therapeutics|July 20, 2024
Evaluating the Effect of Estimating Renal Function With the CKD-EPI 2021 Equation on the ABCD-GENE Score for Clopidogrel Response PredictionMaryam Jamal AlSaeed, Cameron D Thomas, Francesco Franchi, et al.
Journal of the American College of Cardiology|March 26, 2016
Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH StudyFabiana Rollini, Francesco Franchi, Jenny Hu, et al.
Pageof 15